Mesoblast Limited (MESO)
NASDAQ: MESO
· Real-Time Price · USD
14.39
0.87 (6.43%)
At close: Sep 05, 2025, 3:59 PM
14.39
0.00%
After-hours: Sep 05, 2025, 07:05 PM EDT
6.43% (1D)
| Bid | 13.53 |
| Market Cap | 1.77B |
| Revenue (ttm) | 5.67M |
| Net Income (ttm) | -103.35M |
| EPS (ttm) | -0.85 |
| PE Ratio (ttm) | -16.93 |
| Forward PE | -40.97 |
| Analyst | Buy |
| Ask | 15 |
| Volume | 377,835 |
| Avg. Volume (20D) | 242,324.5 |
| Open | 14.00 |
| Previous Close | 13.52 |
| Day's Range | 14.00 - 14.49 |
| 52-Week Range | 6.00 - 22.00 |
| Beta | 1.17 |
About MESO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MESO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MESO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Mesoblast Limited is scheduled to release its earnings on
Feb 25, 2026,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-13.29%
Mesoblast shares are trading lower after the compa...
Unlock content with
Pro Subscription
2 months ago
+11.29%
Mesoblast shares are trading higher after the company announced it is targeting an accelerated FDA approval for its heart failure drug Revascor.
1 month ago · https://www.proactiveinvestors.com
Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rallyShares in Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) surged by nearly 38% following Friday’s successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versus-h...
